New GLP-1 Obesity Drugs: The 2026 Pipeline

Orforglipron, developed by Eli Lilly, is an oral, non-peptide small molecule that activates the GLP-1 receptor: mechanically similar to injectable GLP-1 agonists, but chemically unrelated to the peptide compounds this site otherwise covers.^[1]

Its most advanced published result is ATTAIN-1, a phase 3, randomised, double-blind trial in 3,127 adults with obesity without diabetes, published in the New England Journal of Medicine in November 2025. Over 72 weeks, once-daily orforglipron at 6, 12 or 36 mg produced mean body-weight reductions of 7.5%, 8.4% and 11.2%, against 2.1% with placebo, at every dose (P<0.001).^[1]

Orforglipron is the one molecule in this hub with an FDA approval: on 1 April 2026 the agency approved it as Foundayo for chronic weight management in adults with obesity, or with overweight and at least one weight-related condition. As of September 2026 it has no EMA marketing authorisation.^[13][14]

Amycretin, from Novo Nordisk, is a unimolecular agonist at both the GLP-1 and amylin receptors, tested in subcutaneous and oral forms. Its most advanced published result is a phase 1b/2a randomised, placebo-controlled study in adults with overweight or obesity, published in The Lancet in 2025: subcutaneous amycretin produced substantially greater weight loss than placebo over the study period.^[2]

As of September 2026, amycretin remains investigational. Novo Nordisk has continued into later-phase trials, and neither the FDA nor the EMA has approved it.^[14]

CagriSema combines cagrilintide, an amylin-receptor agonist, with the GLP-1 agonist semaglutide in one weekly injection, both from Novo Nordisk. Its largest published trial, REDEFINE 1, randomised adults with overweight or obesity to CagriSema or placebo; full molecule-level detail on cagrilintide's amylin mechanism and the REDEFINE trial results is covered in the Peptyds cagrilintide research guide.^[8]

As of September 2026, cagrilintide and CagriSema have no FDA approval or EMA marketing authorisation; REDEFINE 1 is registered on ClinicalTrials.gov as active but no longer recruiting.^[8][14]

Eloralintide, Eli Lilly's selective amylin-receptor agonist, reached its most advanced published result in a phase 2 trial in 263 adults with obesity or overweight without diabetes, published in The Lancet in December 2025. Over 48 weeks, weekly eloralintide produced mean body-weight change from -9% to -20% depending on dose, against -0.4% with placebo. A full comparison against retatrutide's triple-agonist mechanism and trial record is in the Peptyds eloralintide vs retatrutide guide.^[9]

Its two phase 3 trials, ENLIGHTEN-1 and ENLIGHTEN-2, were recruiting as of September 2026, and eloralintide has no EMA marketing authorisation.^[9][14]

Petrelintide, discovered by Zealand Pharma and co-developed with Roche under a 2025 licensing agreement, is a long-acting, near-neutral-pH human amylin analogue engineered for chemical stability, described in a 2025 medicinal-chemistry paper. Published clinical evidence so far is limited to pharmacokinetic study design rather than an efficacy readout.^[6]

A phase 2 combination trial pairing petrelintide with the GLP-1 agonist enicepatide, named ZYNERGY, was registered on ClinicalTrials.gov and had not started recruiting as of September 2026. Petrelintide has no FDA approval or EMA marketing authorisation, and it is not sold by Peptyds.^[7][14]

Survodutide, a glucagon and GLP-1 receptor dual agonist from Boehringer Ingelheim and Zealand Pharma, first reported substantial weight reduction in a phase 2, randomised, placebo-controlled, dose-finding trial in adults with obesity without diabetes, published in The Lancet Diabetes & Endocrinology in 2024. Weight change at week 46 ranged from -6.2% to -14.9% across doses, against -2.8% with placebo.^[3]

A phase 3 trial, SYNCHRONIZE-1, randomised 725 adults with obesity to weekly survodutide (3.6 mg or 6.0 mg) or placebo for 76 weeks and was published in the New England Journal of Medicine in August 2026. Survodutide is also in phase 3 development for metabolic dysfunction-associated steatohepatitis. It has no FDA approval or EMA marketing authorisation as of September 2026.^[4][14]

Mazdutide, a GLP-1 and glucagon receptor dual agonist developed by Innovent Biologics and partnered with Eli Lilly outside China, is the only molecule in this hub approved in China: the National Medical Products Administration cleared it for weight management in June 2025 and for type 2 diabetes in September 2025, under the brand name Xinermei.^[11]

Its Chinese phase 3 result, GLORY-1, and the full trial record are covered in the Peptyds mazdutide research guide. Outside China, mazdutide remains investigational, with no FDA approval and no EMA marketing authorisation as of September 2026.^[10][14]

Retatrutide, Eli Lilly's triple GIP, GLP-1 and glucagon receptor agonist, is the only pipeline molecule in this hub that Peptyds carries for research use. Its phase 2 obesity trial, published in the New England Journal of Medicine in 2023, remains its best-known readout; a first peer-reviewed phase 3 result followed in 2026. The full trial record, phase 3 programme and regulatory status are covered in the Peptyds retatrutide guide.^[12]

Maridebart cafraglutide, known by Amgen's development code MariTide, pairs a GLP-1 receptor agonist peptide with a GIP receptor-blocking antibody fragment, engineered for monthly rather than weekly dosing, the widest interval among the nine molecules in this hub.^[5]

Its phase 2 trial, published in the New England Journal of Medicine in June 2025, tested the combination in adults with obesity, with and without type 2 diabetes, over 52 weeks against placebo; weight loss had not plateaued by the final assessment in either group.^[5]

MariTide has no FDA approval or EMA marketing authorisation as of September 2026; Amgen has moved it into phase 3 chronic weight-management trials. It is not sold by Peptyds.^[14]

Reading the pipeline side by side separates three different things that are easy to blur together: mechanism, evidence stage, and regulatory status.

Oral GLP-1 receptor agonist — Orforglipron. Mechanism: GLP-1 receptor, oral small molecule. Most advanced published result: ATTAIN-1 phase 3, NEJM 2025, -11.2% at 36 mg versus -2.1% with placebo at 72 weeks. Regulatory status: FDA-approved as Foundayo (1 April 2026) for chronic weight management; no EMA authorisation.^[1][13]

GLP-1 and amylin receptor agonist — Amycretin. Mechanism: unimolecular GLP-1 plus amylin receptor agonist. Most advanced published result: phase 1b/2a trial, The Lancet, 2025. Regulatory status: investigational; no FDA approval or EMA authorisation.^[2]

Amylin receptor agonist plus GLP-1 — CagriSema (cagrilintide and semaglutide). Mechanism: amylin receptor agonism combined with GLP-1 receptor agonism. Most advanced published result: REDEFINE 1 phase 3, NEJM, 2025. Regulatory status: investigational; no FDA approval or EMA authorisation.^[8]

Amylin receptor agonist — Eloralintide. Mechanism: selective amylin receptor. Most advanced published result: phase 2 trial, The Lancet, December 2025, -9% to -20% versus -0.4% with placebo at 48 weeks. Regulatory status: investigational; phase 3 trials recruiting; no EMA authorisation.^[9]

Amylin receptor agonist — Petrelintide. Mechanism: long-acting human amylin analogue. Most advanced published result: a medicinal-chemistry discovery paper, 2025; no efficacy trial published on PubMed as of September 2026. Regulatory status: investigational; no FDA approval or EMA authorisation.^[6]

Glucagon and GLP-1 receptor dual agonist — Survodutide. Mechanism: glucagon plus GLP-1 receptors. Most advanced published result: SYNCHRONIZE-1 phase 3, NEJM, August 2026. Regulatory status: investigational; no FDA approval or EMA authorisation.^[4]

GLP-1 and glucagon receptor dual agonist — Mazdutide. Mechanism: GLP-1 plus glucagon receptors. Most advanced published result: GLORY-1 phase 3 in China, NEJM, 2025. Regulatory status: approved in China only, NMPA 2025; no FDA approval or EMA authorisation.^[10][11]

GIP, GLP-1 and glucagon receptor triple agonist — Retatrutide. Mechanism: GIP plus GLP-1 plus glucagon receptors. Most advanced published result: phase 2 trial, NEJM, 2023, with a first phase 3 result published in 2026. Regulatory status: investigational; no EMA authorisation.^[12]

GLP-1 agonist and GIP antagonist antibody-peptide conjugate — MariTide (maridebart cafraglutide). Mechanism: GLP-1 receptor agonism plus GIP receptor antagonism, dosed monthly. Most advanced published result: phase 2 trial, NEJM, June 2025. Regulatory status: investigational; no FDA approval or EMA authorisation.^[5]

Of the nine molecules in this hub, Peptyds carries only retatrutide for research use; semaglutide and tirzepatide, the two approved comparators referenced throughout, are also in the Peptyds catalogue. The other eight, orforglipron, amycretin, survodutide, MariTide (maridebart cafraglutide), petrelintide, CagriSema (cagrilintide), eloralintide and mazdutide, are not sold by Peptyds in any form.

That gap tracks the evidence, not demand: most of these compounds are still inside sponsor-controlled development programmes, with no independent research-grade supply chain and, in most cases, no regulatory approval anywhere. A published research result documents research interest; it is not an offer of availability.

Semaglutide and tirzepatide are the two GLP-1-pathway medicines with EMA marketing authorisations, covered fully in the Peptyds GLP-1 peptides guide, including their EPAR status and authorised indications. A three-way comparison of semaglutide, tirzepatide and retatrutide trial data sits in a separate comparison guide. This hub picks up where those two stop: the eight investigational molecules with no marketing authorisation, plus mazdutide's China-only approval.^[14]

Status in this pipeline moves quickly: a phase 2 readout can become a published phase 3 trial within a year, as survodutide's SYNCHRONIZE-1 and orforglipron's ATTAIN-1 both did between 2024 and 2026. Every status in this hub is dated to September 2026 and will move as new peer-reviewed results and regulatory filings appear.^[4][1]